Pure Global AI
NCT06082635Not yet recruiting

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer
Shenzhen TargetRx, Inc.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
TGRX-326
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shenzhen TargetRx, Inc.
Timeline & enrollment
Phase
Phase 3
Start date
Nov 30, 2023
End date
Nov 30, 2028
Enrollment
297 participants
Primary outcome

Progression Free Survival (PFS) by independent review committee (IRC)

Summary

This is a multi-center, randomized, open-label, Phase III clinical trial which compares the
 safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or
 metastatic NSCLC

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06082635
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06082635 through Pure Global AI's free database. This Phase 3 trial is sponsored by Shenzhen TargetRx, Inc. and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 297 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.